Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: Factors predictive of pulmonary damage

Lupus

Volumn 16, Issue 6, 2007, Pages 410-417

  Bertoli, A M ^a   Apte, M ^b   Fessler, B J ^b   Bastian, H M ^b   Reveille, J D ^c   Alarcon G S ^b   Vilá, Luis M ^a,d  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b The University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Disease damage; Lupus pneumonitis; Pulmonary fibrosis; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; ETHNICITY; FEMALE; GENETIC ANALYSIS; HUMAN; LUNG FIBROSIS; LUNG INFARCTION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PHOTOSENSITIVITY; PLEURAL FIBROSIS; PNEUMONIA; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PULMONARY HYPERTENSION; RISK FACTOR; SEROLOGY; SOCIOECONOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AUTOANTIBODIES; AUTOANTIGENS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LONGITUDINAL STUDIES; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 34547172266     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307079042     Document Type: Article

References (69)

1. Orens JB, Martinez FJ, Lynch JP III. Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 20: 159-193.
2. Paran D, Fireman E, Elkayam O. Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome. Autoimmun Rev 2004; 3: 70-75.
3. Lilleby V, Aalokken TM, Johansen B, Forre O. Pulmonary involvement in patients with childhood-onset systemic lupus erythematosus. Clin Exp Rheumatol 2006; 24: 203-208.
4. Rolla G, Brussino L, Bertero MT, Bucca C, Converso M, Caligaris-Cappio F. Respiratory function in systemic lupus erythematosus: relation with activity and severity. Lupus 1996; 5: 38-43.
5. Jonsson H, Nived O, Sturfelt G, Valind S, Jonson B. Lung function in patients with systemic lupus erythematosus and persistent chest symptoms. Br J Rheumatol 1989; 28: 492-499.
6. Traynor AE, Corbridge TC, Eagan AE et al. Prevalence and reversibil-ity of pulmonary dysfunction in refractory systemic lupus: improvement correlates with disease remission following hematopoietic stem cell transplantation. Chest 2005; 127: 1680-1689.
7. Badsha H, Teh CL, Kong KO, Lian TY, Chng HH. Pulmonary hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 2004; 33: 414-421.
8. Cheema GS, Quismorio FP Jr. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 2000; 6: 424-429.
9. Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 1999; 17: 539-545.
10. Barile LA, Jara LJ, Medina-Rodriguez F, Garcia-Figueroa JL, Miranda-Limon JM. Pulmonary hemorrhage in systemic lupus erythematosus. Lupus 1997; 6: 445-448.
11. Chang MY, Fang JT, Chen YC, Huang CC. Diffuse alveolar hemorrhage in systemic lupus erythematosus: a single center retrospective study in Taiwan. Ren Fail 2002; 24: 791-802.
12. Lee CK, Koh JH, Cha HS et al. Pulmonary alveolar hemorrhage in patients with rheumatic diseases in Korea. Scand J Rheumatol 2000; 29: 288-294.
13. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997; 76: 192-202.
14. Koh WH, Thumboo J, Boey ML. Pulmonary haemorrhage in Oriental patients with systemic lupus erythematosus. Lupus 1997; 6: 713-716.
15. Schwab EP, Schumacher HR Jr, Freundlich B, Callegari PE. Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 1993; 23: 8-15.
16. Matthay RA, Schwarz MI, Petty TL et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975; 54: 397-409.
17. Vourlekis JS, Brown KK, Schwarz MI. Acute interstitial pneumonitis: current understanding regarding diagnosis, pathogenesis, and natural history. Semin Respir Crit Care Med 2001; 22: 399-408.
18. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000; 118: 1083-1090.
19. Beresford MW, Cleary AG, Sills JA, Couriel J, Davidson JE. Cardiopulmonary involvement in juvenile systemic lupus erythematosus. Lupus 2005; 14: 152-158.
20. Bernatsky S, Clarke A, Abrahamowicz M, Neville C, Karp I, Pineau CA. A comparison of prospective and retrospective evaluations of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. J Rheumatol 2005; 32: 820-823.
21. Gladman DD. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-376.
22. Sundaramurthy S, Bush TM, Neuwelt CM, Ward MM. Time perspective predicts the progression of permanent organ damage in patients with systemic lupus erythematosus. Lupus 2003; 12: 443-448.
23. Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002; 29: 1398-1400.
24. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 93-96.
25. Alarcon GS, Roseman JM, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) 2004; 43: 202-205.
26. Alarcon GS, McGwin G Jr, Bartolucci AA et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001; 44: 2797-2806.
27. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006; 33: 1570-1577.
28. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus - a 5-yr prospective study. Rheumatology (Oxford) 2004; 43: 1039-1044.
29. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-1959.
30. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42: 276-279.
31. Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol 2001; 28: 525-532.
32. Gilboe IM, Kvien TK, Husby G. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 2001; 28: 266-274.
33. Vila LM, Alarcon GS, McGwin G Jr et al. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) 2004; 43: 358-363.
34. Alarcon GS, Friedman AW, Straaton KV et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in Minority populations: NAture vs. Nurture. Lupus 1999; 8: 197-209.
35. Tan EM. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
36. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
37. Reveille JD, Moulds JM, Ahn C et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998; 41: 1161-1172.
38. U.S. Department of Commerce BotC. Current population reports, Series P-23, No. 28 and Series P-60, No. 68 and subsequent years. Housing and Household Economic Statistics Division, 1995.
39. Liang MH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
40. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248-254.
41. Aarden LA. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann NY Acad Sci 1975; 254: 505-515.
42. Hamilton RG. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988; 31: 496-505.
43. Harris EN. Special report. The second international anti-cardiolipin standardization workshop/the Kingston anti-phospholipid antibody study (KAPS) group. Am J Clin Pathol 1990; 94: 476-484.
44. Edberg JC, Langefeld CD, Wu J et al. Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 2002; 46: 22-2140.
45. Cohen S. Measuring the functional components of social support. In Sarason IG, Sarason BR eds. Social support: theory, research and applications. Martinus Nijhoff, 1985: 73-94.
46. Engle EW. Learned helplessness in systemic lupus erythematosus: Analysis using the rheumatology attitudes index. Arthritis Rheum 1990; 33: 281-286.
47. Pilowsky I. Dimensions of illness behavior as measured by the illness behavior questionnaire: A replication study. J Psychosom Res 1993; 37: 53-62.
48. Mok CC, To CH, Mak A. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 2006; 85: 221-228.
49. Soo MP, Chow SK, Tan CT, Nadior N, Yeap SS, Hoh HB. The spectrum of ocular involvement in patients with systemic lupus erythematosus without ocular symptoms. Lupus 2000; 9: 511-514.
50. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 2004; 43: 1555-1560.
51. Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) 2006; 45: 1144-1147.
52. Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005; 64: 2102-2107.
53. Sinigaglia L, Varenna M, Binelli L et al. Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. J Rheumatol 1999; 26: 1280-1284.
54. Marchesoni A, Messina K, Carrieri P, Sinigaglia L, Tosi S. Pulmonary hypertension and systemic lupus erythematosus. Clin Exp Rheumatol 1983; 1: 247-250.
55. Guarize J, Appenzeller S, Costallat LT. Skin damage occurs early in systemic lupus erythematosus and independently of disease duration in Brazilian patients. Rheumatol Int 2006 (Epub ahead of print).
56. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 1995; 8: 137-145.
57. Becker A, Fischer R, Scherbaum WA, Schneider M. Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus 2001; 10: 809-814.
58. Vilar MJ, Bezerra EL, Sato EI. Skin is the most frequently damaged system in recent-onset systemic lupus erythematosus in a tropical region. Clin Rheumatol 2005; 24: 377-380.
59. Toloza SM, Roseman JM, Alarcon GS et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004; 50: 3177-3186.
60. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA(Ro) antibodies. J Rheumatol 1989; 16: 479-481.
61. Greidinger EL, Hoffman RW. Autoantibodies in the pathogenesis of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31: 437-450, vi.
62. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005; 38: 47-54.
63. Zhao XY, Zhang P, Huang LS, Zhang XH. [The clinical significance of hematological damage in systemic lupus erythematosus and related antibodies]. Zhonghua Nei Ke Za Zhi 2006; 45: 369-371.
64. Bastian HM, Roseman JM, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 152-160.
65. Lopez-Longo FJ, Gonzalez Fernandez CM, Rodriguez MM et al. [Clinical expression of systemic lupus erythematosus with anti-U1-RNP and anti-Sm antibodies]. Rev Clin Esp 1997; 197: 329-335.
66. American Lung Association. Epidemiology and Statistic Unit. Research scientific affairs. Trends in tobacco use 2006. Accessed at http://www.lungusa. org/site.
67. Ghaussy NO, Sibbitt W Jr, Bankhurst AD, Quails CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003; 30: 1215-1221.
68. Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med 1992; 152: 2082-2088.
69. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am 2000; 26: 199-213, v.